FABP4 and metabolic dysfunction-associated steatotic liver disease: In 2009, Milner et al., reported that the adipokine fatty acid-binding protein 4 (FABP4) was elevated in NAFLD patients without HCC versus healthy controls, distinguishing steatohepatitis from simple steatosis and predicting liver inflammation and fibrosis [140].